Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Ionis Pharmaceuticals to $65 from $70 and keeps a Buy rating on the shares. The firm updated its model ahead of the Q3 report, lowering collaboration revenue estimates, modestly increasing SG&A to account for commercial activity ramp and updating the float following the secondary offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals to present data on donidalorsen at ACAAI
- Ionis announces U.S. FDA granted Fast Track Designation for zilganersen
- Biotech Alert: Searches spiking for these stocks today
- Oracle reports Q1 beat, EU says Apple must pay: Morning Buzz
- Ionis Pharmaceuticals 11.5M share Spot Secondary priced at $43.50